Sudarshan Pharma Industries Ltd

Sudarshan Pharma Industries Ltd share price softened by 1.75% to Rs 36.95. The Company's net profit saw a strong growth of 38.68% to Rs 7.78 crore, while revenue from operations gained significantly 24.40% to Rs 216.97 crore in Q3FY26 over Q2FY26. The market capitalization of Specialty Chemicals industry group stocks on BSE stood at Rs 5.51 lakh crore, climbing 10.92%. It has inched up 0.10% over last one week and edged lower by 5.31% in last one month while the market capitalization of Sudarshan Pharma Industries Ltd has sharply increased by 18.24% and 3.12% in the same period respectively. Profit before tax (PBT) of Sudarshan Pharma Industries Ltd stood at Rs 10.8 crore in Q3 FY26, surging by 155.32% year-on-year, and jumping 43.81% quarter-on-quarter. EBITDA came in at Rs 19 crore, expanding by 154.22% YoY and rallying 27.11% sequentially. Total expenses witnessed a sharp rise of 23.64% to Rs 197.74 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 7.26 crore, slightly declining by 9.02% YoY, while employee benefits expense was at Rs 2.04 crore, slipping by 1.45% YoY. For the TTM ended FY26, revenue from operations witnessed a strong growth of 39.21% to Rs 703.06 crore, while net profit jumped 56.11% to Rs 23.37 crore, compared to previous TTM. EBITDA soared by 3635% to Rs 42.61 crore, and PBT soared 52.55% to Rs 30.54 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 2.3 crore in FY26, as against Rs 32.32 crore in FY25. Sudarshan Pharma Industries Ltd surged by 49.90% in last one year, significantly outperforming the benchmark BSE Sensex which has declined by 12.76% during the same period.

Sudarshan Pharma Industries Limited informed the BSE that the proposal to acquire 9.50% equity shares of common stock of Med Therapy Biotechnology Inc., USA, and 1.50% each of the equity shares of common stock of Med Therapy by Chairman & Managing Director Hemal Mehta and Joint Managing Director Sachin Mehta, is currently under due diligence and pending confirmation from the Med Therapy Board of Directors decision and Board of Directors resolution.

Sudarshan Pharma Industries Limited announced that its board approved the acquisition of 24,23,675.64 equity shares, representing 9.50% of the issued and outstanding share capital, of MedTherapy Biotechnology Inc., a U.S.-based cancer cell and gene therapy company founded in 2018. Additionally, Chairman & Managing Director Hemal Mehta and Joint Managing Director Sachin Mehta will acquire 3,82,685.63 shares each, equivalent to 1.50% each, of MedTherapy Biotechnology Inc. The acquisition, to be completed by March 31, 2027, will be funded with a cash consideration in U.S. dollars and requires approval under the Foreign Exchange Management Act, 1999.

Sudarshan Pharma Industries will hold a meeting of the Board of Directors of the Company on 18 June 2026.

Sudarshan Pharma Industries has revised the meeting of the Board of Directors which was scheduled to be held on 22 May 2026. The meeting will now be held on 21 May 2026.

Sudarshan Pharma Industries will hold a meeting of the Board of Directors of the Company on 15 May 2026.

Net profit of Sudarshan Pharma Industries rose 44.80% to Rs 10.73 crore in the quarter ended March 2026 as against Rs 7.41 crore during the previous quarter ended March 2025. Sales rose 36.72% to Rs 220.92 crore in the quarter ended March 2026 as against Rs 161.59 crore during the previous quarter ended March 2025. For the full year,net profit rose 55.64% to Rs 23.30 crore in the year ended March 2026 as against Rs 14.97 crore during the previous year ended March 2025. Sales rose 39.21% to Rs 703.06 crore in the year ended March 2026 as against Rs 505.04 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales220.92161.59 37 703.06505.04 39 OPM %9.149.86 -7.307.73 - PBDT16.8012.37 36 34.3325.64 34 PBT15.7011.54 36 30.5422.84 34 NP10.737.41 45 23.3014.97 56 Powered by Capital Market - Live

Net profit of Sudarshan Pharma Industries rose 35.70% to Rs 9.54 crore in the quarter ended March 2026 as against Rs 7.03 crore during the previous quarter ended March 2025. Sales rose 23.67% to Rs 199.81 crore in the quarter ended March 2026 as against Rs 161.57 crore during the previous quarter ended March 2025. For the full year,net profit rose 56.78% to Rs 21.98 crore in the year ended March 2026 as against Rs 14.02 crore during the previous year ended March 2025. Sales rose 32.84% to Rs 667.50 crore in the year ended March 2026 as against Rs 502.49 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales199.81161.57 24 667.50502.49 33 OPM %9.159.42 -7.347.47 - PBDT14.2311.69 22 32.0824.32 32 PBT13.2310.93 21 28.6721.62 33 NP9.547.03 36 21.9814.02 57 Powered by Capital Market - Live

Sudarshan Pharma Industries will hold a meeting of the Board of Directors of the Company on 30 April 2026.

Net profit of Sudarshan Pharma Industries rose 51.39% to Rs 4.36 crore in the quarter ended December 2025 as against Rs 2.88 crore during the previous quarter ended December 2024. Sales rose 45.26% to Rs 168.01 crore in the quarter ended December 2025 as against Rs 115.66 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales168.01115.66 45 OPM %6.476.90 - PBDT6.114.48 36 PBT5.203.85 35 NP4.362.88 51 Powered by Capital Market - Live